TPW
GMAB icon

Transatlantique Private Wealth’s Genmab GMAB Stock Holding History

Transatlantique Private Wealth’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,271
Closed -$221K – 217
2023
Q3 		$221K Hold
6,271
– – 0.12% 188
2023
Q2 		$238K Sell
6,271
-1,467
-19% -$58.5K 0.12% 185
2023
Q1 		$292K Sell
7,738
-865
-10% -$33.2K 0.16% 172
2022
Q4 		$365K Hold
8,603
– – 0.22% 140
2022
Q3 		$276K Buy
+8,603
New +$302K 0.18% 171

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Transatlantique Private Wealth's GMAB Position: Q4 2023 in Review

Transatlantique Private Wealth sold out of Genmab (GMAB) in Q4 2023, closing a stake of 6,271 shares — an estimated $221K sold.

Transatlantique Private Wealth first reported a position in GMAB in Q3 2022 and held it in 5 quarters. The position peaked at $365K in Q4 2022. 225 funds tracked by Wall St. Rank hold GMAB as of Q4 2023.

  • Transatlantique Private Wealth reported no remaining Genmab position as of Q4 2023 after selling out during the quarter.
  • Transatlantique Private Wealth sold 6,271 Genmab shares in Q4 2023, an estimated $221K.
  • Transatlantique Private Wealth first reported a position in Genmab in Q3 2022 and held it in 5 quarters.
  • Transatlantique Private Wealth's Genmab position peaked at $365K in Q4 2022.
  • 225 funds tracked by Wall St. Rank held Genmab as of Q4 2023.

Based on Transatlantique Private Wealth's 13F filing for Q4 2023, filed 13 Feb 2024.